Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
作者： Jeffrey James Roix , Dean Welsch , Saurabh Saha , Gary DeCrescenzo
DOI:
关键词:
摘要: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in subject, which is refractory resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods identifying subject having who would benefit from therapy with an ERK inhibiting phosphorylation RSK cell that inhibitor.
lens.org 参考文章(82)
Farnaz Absalan, Mostafa Ronaghi, Molecular inversion probe assay. Methods of Molecular Biology. ,vol. 396, pp. 315- 330 ,(2007) , 10.1007/978-1-59745-515-2_20
Urban Scheuring, Ingo Bernard, Claus Garbe, Friedegund Meier, Birgit Schittek, Combination therapy comprising diaryl ureas for treating diseases ,(2006)
Zhan Yao, Neilawattie M. Torres, Anthony Tao, Yijun Gao, Lusong Luo, Qi Li, Elisa de Stanchina, Omar Abdel-Wahab, David B. Solit, Poulikos I. Poulikakos, Neal Rosen, BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition Cancer Cell. ,vol. 28, pp. 370- 383 ,(2015) , 10.1016/J.CCELL.2015.08.001
Paul R Massey, Vinay Prasad, William D Figg, Tito Fojo, Multiplying therapies and reducing toxicity in metastatic melanoma Cancer Biology & Therapy. ,vol. 16, pp. 1014- 1018 ,(2015) , 10.1080/15384047.2015.1046650
Neel M. Fofaria, Dennie T. Frederick, Ryan J. Sullivan, Keith T. Flaherty, Sanjay K. Srivastava, Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget. ,vol. 6, pp. 40535- 40556 ,(2015) , 10.18632/ONCOTARGET.5755
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion-Sileni, Kamil Drucis, Ivana Krajsova, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V Long, Keith Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D Rubin, Shonda M Little, Dirk Schadendorf, None, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib The New England Journal of Medicine. ,vol. 372, pp. 30- 39 ,(2015) , 10.1056/NEJMOA1412690
Paola Queirolo, Virginia Picasso, Francesco Spagnolo, Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treatment Reviews. ,vol. 41, pp. 519- 526 ,(2015) , 10.1016/J.CTRV.2015.04.010
Maria E. Arcila, Alexander Drilon, Brooke E. Sylvester, Christine M. Lovly, Laetitia Borsu, Boris Reva, Mark G. Kris, David B. Solit, Marc Ladanyi, MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking Clinical Cancer Research. ,vol. 21, pp. 1935- 1943 ,(2015) , 10.1158/1078-0432.CCR-14-2124
Paul Hardenbol, Johan Banér, Maneesh Jain, Mats Nilsson, Eugeni A Namsaraev, George A Karlin-Neumann, Hossein Fakhrai-Rad, Mostafa Ronaghi, Thomas D Willis, Ulf Landegren, Ronald W Davis, Multiplexed genotyping with sequence-tagged molecular inversion probes Nature Biotechnology. ,vol. 21, pp. 673- 678 ,(2003) , 10.1038/NBT821
K H T Paraiso, I V Fedorenko, L P Cantini, A C Munko, M Hall, V K Sondak, J L Messina, K T Flaherty, K S M Smalley, Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy British Journal of Cancer. ,vol. 102, pp. 1724- 1730 ,(2010) , 10.1038/SJ.BJC.6605714